REVOLUTION MEDICINES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.41 USD | +1.08% |
|
+5.80% | +37.41% |
| 05-09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
| 05-08 | Revolution Medicines Q1 Net Loss Narrows | MT |
Presenter SpeechPeter Lawson (Analysts)Good afternoon. My name is Peter Lawson. I'm one of the...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâs research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâs RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
Calendar
20/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
39.41
USD
Average target price
44.82
USD
Spread / Average Target
+13.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.41% | 6.5B | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Transcript : Revolution Medicines, Inc. Presents at Barclays Virtual Fireside Chat Series, Jun-15-2023 12
